Operating Lease, Right-of-Use Asset of Apellis Pharmaceuticals, Inc. from 01 Jan 2019 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of lessee's right to use underlying asset under operating lease.
Summary
Apellis Pharmaceuticals, Inc. quarterly Operating Lease, Right-of-Use Asset in USD history and change rate from 01 Jan 2019 to 30 Sep 2025.
  • Apellis Pharmaceuticals, Inc. Operating Lease, Right-of-Use Asset for the quarter ending 30 Sep 2025 was $19,720,000, a 16% increase year-over-year.
Source SEC data
View on sec.gov
Operating Lease, Right-of-Use Asset, Quarterly (USD)
Operating Lease, Right-of-Use Asset, YoY Quarterly Change (%)

Apellis Pharmaceuticals, Inc. Quarterly Operating Lease, Right-of-Use Asset (USD)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $19,720,000 +$2,660,000 +16% 30 Sep 2025 10-Q 30 Oct 2025 2025 Q3
Q2 2025 $14,637,000 -$1,684,000 -10% 30 Jun 2025 10-Q 31 Jul 2025 2025 Q2
Q1 2025 $15,251,000 +$257,000 +1.7% 31 Mar 2025 10-Q 07 May 2025 2025 Q1
Q4 2024 $16,083,000 -$662,000 -4% 31 Dec 2024 10-Q 30 Oct 2025 2025 Q3
Q3 2024 $17,060,000 +$1,576,000 +10% 30 Sep 2024 10-Q 05 Nov 2024 2024 Q3
Q2 2024 $16,321,000 -$405,000 -2.4% 30 Jun 2024 10-Q 01 Aug 2024 2024 Q2
Q1 2024 $14,994,000 -$2,860,000 -16% 31 Mar 2024 10-Q 07 May 2024 2024 Q1
Q4 2023 $16,745,000 -$2,002,000 -11% 31 Dec 2023 10-K 28 Feb 2025 2024 FY
Q3 2023 $15,484,000 -$4,038,000 -21% 30 Sep 2023 10-Q 01 Nov 2023 2023 Q3
Q2 2023 $16,726,000 -$4,029,000 -19% 30 Jun 2023 10-Q 31 Jul 2023 2023 Q2
Q1 2023 $17,854,000 -$2,118,000 -11% 31 Mar 2023 10-Q 04 May 2023 2023 Q1
Q4 2022 $18,747,000 -$1,154,000 -5.8% 31 Dec 2022 10-K/A 29 Feb 2024 2023 FY
Q3 2022 $19,522,000 -$1,408,000 -6.7% 30 Sep 2022 10-Q 07 Nov 2022 2022 Q3
Q2 2022 $20,755,000 -$1,184,000 -5.4% 30 Jun 2022 10-Q 08 Aug 2022 2022 Q2
Q1 2022 $19,972,000 -$2,546,000 -11% 31 Mar 2022 10-Q 04 May 2022 2022 Q1
Q4 2021 $19,901,000 +$2,182,000 +12% 31 Dec 2021 10-K 21 Feb 2023 2022 FY
Q3 2021 $20,930,000 +$2,385,000 +13% 30 Sep 2021 10-Q 08 Nov 2021 2021 Q3
Q2 2021 $21,939,000 +$8,980,000 +69% 30 Jun 2021 10-Q 09 Aug 2021 2021 Q2
Q1 2021 $22,518,000 +$8,803,000 +64% 31 Mar 2021 10-Q 28 Apr 2021 2021 Q1
Q4 2020 $17,719,000 +$3,609,000 +26% 31 Dec 2020 10-K 28 Feb 2022 2021 FY
Q3 2020 $18,545,000 +$5,212,217 +39% 30 Sep 2020 10-Q 02 Nov 2020 2020 Q3
Q2 2020 $12,959,000 +$6,359,000 +96% 30 Jun 2020 10-Q 30 Jul 2020 2020 Q2
Q1 2020 $13,715,000 +$7,115,000 +108% 31 Mar 2020 10-Q 29 Apr 2020 2020 Q1
Q4 2019 $14,110,000 +$8,598,135 +156% 31 Dec 2019 10-K 25 Feb 2021 2020 FY
Q3 2019 $13,332,783 30 Sep 2019 10-Q 05 Nov 2019 2019 Q3
Q2 2019 $6,600,000 30 Jun 2019 10-Q 31 Jul 2019 2019 Q2
Q1 2019 $6,600,000 31 Mar 2019 10-Q 07 May 2019 2019 Q1
Q4 2018 $5,511,865 01 Jan 2019 10-K 27 Feb 2020 2019 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.